Haoxi Health Technology Ltd (NASDAQ: HAO) has announced a definitive agreement with investors for a registered direct offering intended to raise about $4 million. According to the company’s announcement, the deal involves the purchase and sale of 10,000,000 Class A Ordinary Shares, each with a par value of $0.32.
The offering price is set at $0.40 per share. The company also notes that investors may receive pre-funded warrants in lieu of shares, which can affect how the investment is structured and how potential future dilution or exercise mechanics are handled—important considerations for anyone tracking capital-raising outcomes.
For small- and mid-size business owners, the practical takeaway is straightforward: when a public company moves forward with a registered direct offering, it signals an active capital plan that can influence market expectations around liquidity, runway, and execution. While the filing details and full terms aren’t included in the brief summary, the headline economics—share count, structure (shares vs. pre-funded warrants), and price—are clear enough to assess the scale of the transaction.
GlobeNewswire — Public Cos. reports that Haoxi entered into this arrangement through a definitive agreement with certain investors, following the registered direct offering approach. As always, owners watching sector dynamics may want to monitor whether subsequent updates provide additional clarity on proceeds use and timing, but this announcement alone establishes the size and pricing of the share sale.
Source: GlobeNewswire — Public Cos.
